Pasithea Therapeutics (KTTA) Common Equity (2020 - 2026)
Pasithea Therapeutics (KTTA) posted Common Equity of $54.8 million for Q1 2026, down 0.74% sequentially from $55.2 million in Q4 2025, and up 322.32% YoY from $13.0 million in Q1 2025.
Pasithea Therapeutics (KTTA) Common Equity (2020 - 2026) Analysis & Trends
Pasithea Therapeutics has reported Common Equity for 7 years, with the latest figure at $54.8 million in Q1 2026.
- Quarterly Common Equity rose 322.32% year-over-year to $54.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54.8 million (up 322.32% YoY) and the FY2025 annual result came in at $55.2 million, up 273.54% from the prior year.
- Common Equity retreated to $54.8 million in Q1 2026 per KTTA's latest filing, from $55.2 million in the prior quarter.
- Over five years, Common Equity peaked at $55.2 million in Q4 2025 and troughed at $12.2 million in Q3 2025.
- A 5-year average of $31.5 million and a median of $28.4 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2024: Common Equity jumped 10817.73% in 2022, then tumbled 54.55% in 2024.
- Over 5 years, Common Equity stood at $42.5 million in 2022, then plunged by 44.94% to $23.4 million in 2023, then slumped by 36.82% to $14.8 million in 2024, then soared by 273.54% to $55.2 million in 2025, then fell by 0.74% to $54.8 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $54.8 million, $55.2 million, and $12.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Pasithea Therapeutics | 16.97 Mn | 16.97 Mn | - | 49.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 54.81 Mn |
| Dec 31, 2025 | 55.22 Mn |
| Sep 30, 2025 | 12.21 Mn |
| Jun 30, 2025 | 15.18 Mn |
| Mar 31, 2025 | 12.98 Mn |
| Dec 31, 2024 | 14.78 Mn |
| Sep 30, 2024 | 17.81 Mn |
| Jun 30, 2024 | 16.18 Mn |
| Mar 31, 2024 | 19.88 Mn |
| Dec 31, 2023 | 23.40 Mn |
| Sep 30, 2023 | 28.37 Mn |
| Jun 30, 2023 | 35.59 Mn |
| Mar 31, 2023 | 39.14 Mn |
| Dec 31, 2022 | 42.50 Mn |
| Sep 30, 2022 | 46.79 Mn |
| Jun 30, 2022 | 51.32 Mn |
| Mar 31, 2022 | 49.98 Mn |
| Dec 31, 2021 | 51.42 Mn |
| Sep 30, 2021 | 16.48 Mn |
| Jun 30, 2021 | 470,078.00 |